Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4635 in advanced solid malignancies
NCT02740985Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2016
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of imaradenant in malignant solid tumor, non-small cell lung cancer (NSCLC), metastatic castration-resistant prostate cancer (mCRPC) and 1 more (18 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of Dose-Limiting Toxicities (DLTs) in patients receiving AZD4635 monotherapy at 3 weeks, Incidence of Dose-Limiting Toxicities (DLTs) in patients receiving AZD4635 in combination with durvalumab at 7 weeks and 2 more. Started Jun 2016; status: completed.
02
Drugs
imaradenant
03
Conditions
malignant solid tumornon-small cell lung cancer (NSCLC)metastatic castration-resistant prostate cancer (mCRPC)colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT02740985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02740985.